logo
Plus   Neg
Share
Email

Nordic Nanovector' Betalutin Gets Fast-track Designation From FDA For Marginal Zone Lymphoma

Nordic Nanovector ASA (NVO) said Monday that the U.S. Food and Drug Administration has granted Fast Track designation for investigating Betalutin for the treatment of adult patients with relapsed or refractory marginal zone lymphoma or MZL who have received at least two prior systemic therapies.

The company said it is evaluating the opportunity to develop Betalutin as a single-agent treatment for MZL, a rare type of non-Hodgkin's lymphoma or NHL.

Betalutin has demonstrated a very promising clinical effect in nine MZL patients in the Phase 1/2a LYMRIT 37-01 trial

Betalutin has received Orphan Drug Designation in the European Union for the treatment of MZL and has applied for the equivalent designation in the US.

Marginal Zone Lymphoma is an incurable and long-term debilitating disease due to its effects on the spleen, lymph nodes and bone marrow, as well as the increased risk of infection.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The media mogul and Billionaire Sumner Redstone passed away on Tuesday at the age of 97, his family's holding company National Amusements said in a statement on Wednesday. He was Chairman Emeritus of ViacomCBS and chief executive officer of National Amusements. Customers in the U.S. are preferring digital or touchless payment methods due to concerns arising from the COVID-19 pandemic, a survey said. According to the survey by Rapyd Financial Network, the coronavirus pandemic has raised health and safety concerns around using cash and coins, and is accelerating the pre-existing trend toward digital transactions. American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until December 31, 2020 in response to lower travel demand due to the coronavirus pandemic. This means that the travelers need not pay penalties for changing the origin and destination cities.
Follow RTT